BIOMAT Database Logo BIOMAT Database Logo

Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease. 2024

Iskra Pusic, and Catherine Lee, and Muthu Veeraputhiran, and Chelsea Minor, and John F DiPersio
Washington University School of Medicine, Division of Oncology, St. Louis, MO, USA. iskrapusic@wustl.edu.

UI MeSH Term Description Entries
D009570 Nitriles Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE. Nitrile
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000081 Acetamides Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis.
D000092122 Bronchiolitis Obliterans Syndrome Bronchiolitis obliterans complication from allogenic HEMATOPOIETIC STEM CELL TRANSPLANTATION and LUNG TRANSPLANTATION. BOS Bronchiolitis Obliterans Syndrome,Chronic Graft-Versus-Host Disease,Obstructive CLAD,Obstructive Chronic Lung Allograft Dysfunction,Bronchiolitis Obliterans Syndromes,CLAD, Obstructive,Chronic Graft Versus Host Disease,Chronic Graft-Versus-Host Diseases,Disease, Chronic Graft-Versus-Host,Graft-Versus-Host Disease, Chronic,Graft-Versus-Host Diseases, Chronic,Obstructive CLADs,Syndrome, Bronchiolitis Obliterans
D018380 Hematopoietic Stem Cell Transplantation Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms. Stem Cell Transplantation, Hematopoietic,Transplantation, Hematopoietic Stem Cell

Related Publications

Iskra Pusic, and Catherine Lee, and Muthu Veeraputhiran, and Chelsea Minor, and John F DiPersio
Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease.
April 2021, Bone marrow transplantation,
Iskra Pusic, and Catherine Lee, and Muthu Veeraputhiran, and Chelsea Minor, and John F DiPersio
Belumosudil for chronic graft-versus-host disease.
May 2022, Drugs of today (Barcelona, Spain : 1998),
Iskra Pusic, and Catherine Lee, and Muthu Veeraputhiran, and Chelsea Minor, and John F DiPersio
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
July 2021, The New England journal of medicine,
Iskra Pusic, and Catherine Lee, and Muthu Veeraputhiran, and Chelsea Minor, and John F DiPersio
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease.
May 2019, Bone marrow transplantation,
Iskra Pusic, and Catherine Lee, and Muthu Veeraputhiran, and Chelsea Minor, and John F DiPersio
Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
May 2022, Pediatric dermatology,
Iskra Pusic, and Catherine Lee, and Muthu Veeraputhiran, and Chelsea Minor, and John F DiPersio
Ruxolitinib for Chronic Graft-versus-Host Disease.
October 2021, The New England journal of medicine,
Iskra Pusic, and Catherine Lee, and Muthu Veeraputhiran, and Chelsea Minor, and John F DiPersio
Ruxolitinib for Chronic Graft-versus-Host Disease.
October 2021, The New England journal of medicine,
Iskra Pusic, and Catherine Lee, and Muthu Veeraputhiran, and Chelsea Minor, and John F DiPersio
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
May 2020, The New England journal of medicine,
Iskra Pusic, and Catherine Lee, and Muthu Veeraputhiran, and Chelsea Minor, and John F DiPersio
Ruxolitinib for steroid-refractory acute graft-versus-host disease.
February 2020, Transplant international : official journal of the European Society for Organ Transplantation,
Iskra Pusic, and Catherine Lee, and Muthu Veeraputhiran, and Chelsea Minor, and John F DiPersio
Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.
May 2020, Expert opinion on investigational drugs,
Copied contents to your clipboard!